Denali Therapeutics Inc. Increase (Decrease) in Accounts Payable
Denali Therapeutics Inc. (DNLI) reported Increase (Decrease) in Accounts Payable of $4.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Denali Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $227.00K, a 91.26% decline year-over-year.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $3.88M.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$3.41M, a 365.01% decline year-over-year.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$4.07M.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2025 was -$7.52M, a 623.31% decline from fiscal 2024.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.44M, a 40.89% decline from fiscal 2023.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.43M, a 6.90% increase from fiscal 2022.
- Denali Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2022 was $2.27M, a 38.62% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $227.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.10M 10-Q · filed 2026-08-06 | $694.00K derived: sum of 3 quarters · filed 2026-08-06 | -$3.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.88M 10-Q · filed 2026-05-07 | $467.00K derived: sum of 2 quarters · filed 2026-05-07 | -$3.60M derived: sum of 3 quarters · filed 2026-05-07 | -$1.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$7.48M derived: sum of 2 quarters · filed 2026-02-26 | -$4.88M derived: sum of 3 quarters · filed 2026-08-06 | -$7.52M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.47M derived: sum of 2 quarters · filed 2026-08-06 | -$4.11M 10-Q · filed 2025-11-06 | -$2.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$43.00K 10-Q · filed 2026-08-06 | $1.24M derived: sum of 3 quarters · filed 2026-08-06 | -$3.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.64M 10-Q · filed 2026-05-07 | -$1.35M derived: sum of 2 quarters · filed 2026-05-07 | -$5.72M derived: sum of 3 quarters · filed 2026-05-07 | -$1.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.09M derived: sum of 2 quarters · filed 2026-02-26 | $802.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.44M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$4.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$484.00K derived: sum of 2 quarters · filed 2025-11-06 | $151.00K 10-Q · filed 2025-11-06 | -$1.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $4.52M 10-Q · filed 2025-08-11 | $2.44M derived: sum of 3 quarters · filed 2026-02-26 | -$1.52M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $635.00K 10-Q · filed 2025-05-06 | -$1.45M derived: sum of 2 quarters · filed 2026-02-26 | -$5.41M derived: sum of 3 quarters · filed 2026-02-26 | -$632.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.04M derived: sum of 2 quarters · filed 2026-02-26 | -$1.27M derived: sum of 3 quarters · filed 2026-02-26 | $2.43M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $814.00K derived: sum of 2 quarters · filed 2024-11-06 | $4.51M 10-Q · filed 2024-11-06 | $2.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $8.47M 10-Q · filed 2024-08-01 | $6.76M derived: sum of 3 quarters · filed 2025-02-27 | $8.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.70M 10-Q · filed 2024-05-07 | $1.98M derived: sum of 2 quarters · filed 2025-02-27 | $3.88M derived: sum of 3 quarters · filed 2025-02-27 | $4.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $187.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.03M derived: sum of 3 quarters · filed 2025-02-27 | $2.27M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.74M derived: sum of 2 quarters · filed 2023-11-07 | $3.99M 10-Q · filed 2023-11-07 | $3.91M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $839.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.09M 10-Q · filed 2023-08-08 | $2.01M derived: sum of 3 quarters · filed 2024-02-28 | $2.79M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.25M 10-Q · filed 2023-05-08 | $1.17M derived: sum of 2 quarters · filed 2024-02-28 | $1.95M derived: sum of 3 quarters · filed 2024-02-28 | $4.33M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $704.00K derived: sum of 2 quarters · filed 2024-02-28 | $3.08M derived: sum of 3 quarters · filed 2024-02-28 | $3.71M 10-K · filed 2024-02-28 |
| 2021-09-30 | $782.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.16M derived: sum of 2 quarters · filed 2022-11-03 | $3.78M 10-Q · filed 2022-11-03 | $2.01M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.00M 10-Q · filed 2022-08-08 | $1.23M derived: sum of 3 quarters · filed 2023-02-27 | $2.12M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $623.00K 10-Q · filed 2022-05-05 | -$1.15M derived: sum of 2 quarters · filed 2023-02-27 | -$256.00K derived: sum of 3 quarters · filed 2023-02-27 | -$708.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$879.00K derived: sum of 2 quarters · filed 2023-02-27 | -$1.33M derived: sum of 3 quarters · filed 2023-02-27 | -$1.62M 10-K · filed 2023-02-27 |
| 2020-09-30 | $891.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $439.00K derived: sum of 2 quarters · filed 2021-11-04 | $147.00K 10-Q · filed 2021-11-04 | $714.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$452.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$744.00K 10-Q · filed 2021-08-04 | -$177.00K derived: sum of 3 quarters · filed 2022-02-28 | -$1.01M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$292.00K 10-Q · filed 2021-05-05 | $275.00K derived: sum of 2 quarters · filed 2022-02-28 | -$562.00K derived: sum of 3 quarters · filed 2022-02-28 | -$1.22M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$270.00K derived: sum of 2 quarters · filed 2022-02-28 | -$932.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.03M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$837.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.50M derived: sum of 2 quarters · filed 2020-11-05 | $466.00K 10-Q · filed 2020-11-05 | -$1.29M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$662.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.30M 10-Q · filed 2020-08-07 | -$458.00K derived: sum of 3 quarters · filed 2021-02-26 | -$6.32M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $1.97M 10-Q · filed 2020-05-07 | $204.00K derived: sum of 2 quarters · filed 2021-02-26 | -$5.66M derived: sum of 3 quarters · filed 2021-02-26 | $2.39M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$7.62M derived: sum of 2 quarters · filed 2021-02-26 | $425.00K derived: sum of 3 quarters · filed 2021-02-26 | -$526.00K 10-K · filed 2021-02-26 |
| 2018-09-30 | -$5.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $2.19M derived: sum of 2 quarters · filed 2019-11-06 | $1.24M 10-Q · filed 2019-11-06 | $1.12M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $8.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $7.09M 10-Q · filed 2019-08-06 | $6.98M derived: sum of 3 quarters · filed 2020-02-27 | $7.75M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$951.00K 10-Q · filed 2019-05-08 | -$1.06M derived: sum of 2 quarters · filed 2020-02-27 | -$298.00K derived: sum of 3 quarters · filed 2020-02-27 | -$26.00K derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $653.00K derived: sum of 2 quarters · filed 2020-02-27 | $925.00K derived: sum of 3 quarters · filed 2020-02-27 | $207.00K 10-K · filed 2020-02-27 |
| 2017-09-30 | $764.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.04M derived: sum of 2 quarters · filed 2018-11-08 | $318.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $272.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$446.00K 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$718.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $161.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |